Vanessa Pataia,  —

Novartis has awarded a total of $300,000 to two tech companies, honoring each for work done to improve the mobility and independence of people living with multiple sclerosis (MS). The top winner of the Novartis Innovation Prize: Assistive Tech for…

Psychosis and cognitive difficulties may be initial symptoms of relapsing‐remitting multiple sclerosis (RRMS), a case report says. “A case report revealing acute onset psychosis and cognitive impairment as primary manifestation in relapsing‐remitting multiple sclerosis” was published in the journal…

Autobahn Therapeutics announced its launch with $76 million in financing to support work on therapies for central nervous system (CNS) disorders, including ABX-002, its lead candidate to treat diseases marked by the loss of myelin, such as …

The Multiple Sclerosis Association of America (MSAA) is opening its resources to people with multiple sclerosis (MS) during COVID-19, including a webinar series on the pandemic and easier access to its support programs, the association…

A patient registry of multiple sclerosis (MS) among veterans of the U.S. military has been created to allow for better clinical management of these people and to inform future research. The registry is described in the study “…

The neurotechnology company Helius Medical Technologies has received authorization from Health Canada to market its portable neuromodulation stimulator (PoNS) device to treat gait deficit in patients with mild-to-moderate multiple sclerosis…

Changing a person’s diet to reduce the amount of methionine (amino acid found in food) could delay the development and progression of inflammatory and autoimmune disorders, including multiple sclerosis (MS). That finding was described in the study “…

Having other health conditions, or comorbidities, along with multiple sclerosis (MS) does not increase a person’s risk of being hospitalized due to MS-specific symptoms, although it does raise the rate of all-cause hospital admissions, a study found.  The finding was described…

Scientists discovered new interaction between immune cells from the central nervous system (CNS) — consisting of the brain and spinal cord — and immune cells from the blood that may lead to new treatments for multiple sclerosis (MS) and other neurological diseases.

Harvard professor and scientist Francisco Quintana, PhD, has been awarded the 2019 Barancik Prize for Innovation in MS Research for his work in understanding what causes multiple sclerosis (MS), and how to stop its development. Quintana has developed innovative research programs that use cutting-edge technology to help…

Interaction between various Epstein-Barr virus traits and the composition of certain genes affects the risk of developing multiple sclerosis (MS), a study reports. The study, “The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis,” was published in the journal…

People living close to major roads or highways are at a greater risk of multiple sclerosis (MS), a database study of people in metropolitan Vancouver reports. Parks and other green spaces in urban areas that might lower exposure to air pollutants did not affect a person’s overall risk of developing MS,…

A new study has found a link between the amount of fat in the blood and changes to the arteries surrounding the necks and skulls of people with multiple sclerosis (MS). The finding was described in the study “Lipoprotein(a) Levels Are Associated with the…

BioMed X announced a new collaboration with Merck to create a joint research group to investigate the role of the intestinal epithelial barrier in the development and progression of autoimmune diseases, including multiple sclerosis (MS). The intestinal epithelial barrier is a physical border between the gut and the rest…

A new clinical trial is comparing the best available therapies to an experimental stem cell therapy to treat severe forms of relapsing multiple sclerosis (MS). At the moment, more than a dozen therapies have been approved by the U.S. Food and Drug Administration for the treatment of relapsing forms…